All posts by imreal

Use of Pembrolizumab Provided Long-Term Benefits in Patients With Metastatic Melanoma, 10-Year Look Shows


Doctor in white coat posing near window

In a study published in JAMA Oncology, Dr. Igor Puzanov took a 10-year look at pembrolizumab use in patients with advanced melanoma

“The study reinforces the fact that immunotherapy can significantly extend the life of patients with melanoma and even lead to cures,” said Dr. Puzanov.

A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published Thursday in the journal JAMA Oncology provides new insights into an important question: whether BRAF V600E/K mutation status or previous BRAF inhibitor (BRAFi) therapy with or without a MEK inhibitor (MEKi) affects response to pembrolizumab (brand name Keytruda) in patients with advanced melanoma.

This retrospective analysis of three randomized clinical trials (KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006) involved 1,558 patients with advanced melanoma and known BRAF tumor status (BRAF wild-type or BRAF V600E/K-mutant melanoma) who had all been treated with pembrolizumab, some of whom had undergone prior treatment with BRAF inhibitors with or without MEK inhibitors.

Patients with BRAF wild-type and BRAF V600E/K-mutant melanoma had objective response rates (ORRs) of 39.8% and 34.3%, respectively, and similar respective rates of both 4-year progression-free survival (PFS; 22.9% and 19.8%) and overall survival (OS; 37.5% and 35.1%).

Patients with BRAF V600E/K-mutant melanoma who received previous BRAFi with or without MEKi had baseline characteristics with worse prognosis — lower ORR (28.4% vs 44.2%), 4-year PFS (15.2% vs 27.8%), and OS (26.9% vs 49.3%) — compared to those who had not received earlier targeted therapy.

The results of this study support the use of pembrolizumab for the treatment of advanced melanoma regardless of BRAF V600E/K mutation status or prior BRAF inhibitor, with or without MEK inhibitor therapy.

“Our findings confirmed the long-term, lasting benefits of pembrolizumab for patients with unresectable advanced melanoma and show that the effect is seen regardless of BRAF mutation status — and regardless of earlier treatment with a BRAF-targeting therapy,” says Dr. Puzanov, who is first author on the new publication. “Coupled with what we know from separate studies about nivolumab, we see a clear picture of the benefits immune checkpoint inhibitors have had for thousands of people with advanced melanoma over the last decade.”

Some 40% of patients with metastatic melanoma have BRAF mutations, meaning a particular gene and protein in their tumor cells is modified. Of that group, 90% have an activating BRAF mutation.

“Our long-term view provides evidence to support giving immunotherapy early in a patient’s treatment, before turning to targeted therapies. This course of treatment is now the standard of care, but this is important affirmation for this approach, which was not standard at the time these patients were treated,” Dr. Puzanov notes.

These study findings may help explain the striking decline in deaths from melanoma reported by the American Cancer Society (ACS) a few months ago. A January 2020 report from the ACS documented a 7%-per-year decline in the overall melanoma death rate between 2013 and 2017 in people ages 20 to 64.

“The study reinforces the fact that immunotherapy can significantly extend the life of patients with melanoma and even lead to cures,” Dr. Puzanov says. “But importantly, we also still see a role for targeted therapies. Having both of these treatment options at our disposal has helped to drive incredible progress against in a cancer type that was almost universally fatal a decade ago.”

The authors note that ongoing randomized controlled trials should support clearer and more specific conclusions about the optimal sequencing of these treatments.

Co-authors on this work include Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Caroline Robert, MD, PhD, of Gustave Roussy, Paris-Sud University, and Omid Hamid, MD, of The Angeles Clinic and Research Institute. A full list of contributors can be found at the study link.

###

For an online version of this release, please visit: https://www.roswellpark.org/newsroom/202007-use-pembrolizumab-provided-long-term-benefits-patients-metastatic-melanoma-10-year

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at http://www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

Share article on social media or email:

Congoleum® Corporation Initiates Voluntary Reorganization Proceedings


“Congoleum is EBITDA-positive and growing, but we must achieve a more viable capital structure,” said Congoleum CEO Chris O’Connor. ” Today’s reorganization announcement represents a decisive, positive step that will strengthen our position for future prosperity.

Congoleum®, one of America’s oldest resilient flooring manufacturers, founded in 1886, today announced that it has initiated voluntary reorganization proceedings in the District of New Jersey under Chapter 11 of the U.S. Bankruptcy Code. The Company intends to use the court process to pursue a financial restructuring designed to reduce its current debt load, maximize value and position the Company for long-term success. Congoleum plans to continue operating in the ordinary course of business, under the court’s supervision, and remains committed to being the consumer-centric Company that has shaped the resilient flooring industry for more than a century.

“Congoleum is EBITDA-positive and growing, but we must achieve a more viable capital structure,” said Congoleum CEO Chris O’Connor. ” Today’s reorganization announcement represents a decisive, positive step that will strengthen our position for future prosperity. Over the past 134 years, Congoleum has earned the distinction of being one of the most respected and well-recognized national flooring brands. We will continue serving our customers, employees and other stakeholders, operating business as usual throughout this process.”

Congoleum has a long and storied history as a market-leader driven by an entrepreneurial spirit and committed to excellence in design, quality and innovation. The invention of in-register embossing for sheet goods, introducing the world’s first rigid and groutable LVT and most recently the launch of its patented, digitally printed, PVC-free Cleo™ family of products are but a few of the innovations that have not only driven the industry forward but have quite literally changed the way the world sees resilient flooring.

“Despite our numerous achievements during the past several years, the Company remains saddled with high legacy debt and increasing costs associated with running the business. As the industry adapts to changes in product mix, import vs. domestic production, and rising operating costs, these contributing factors make the current level of debt unsustainable,” O’Connor explained. “For the last few months, we have engaged in discussions with our lenders to evaluate a range of potential strategic plans for the Company. Ultimately, we determined that the best way to protect the Company, for the benefit of all stakeholders, is to reorganize through this court-supervised process.”

Stressing that it is “business as usual” at Congoleum, O’Connor noted that the Company had proactively filed expected motions as part of the court-supervised process and intends to work closely with creditors, customers and employees to identify value-maximizing restructuring plans that will benefit all stakeholders.

“Congoleum is a heritage American brand that has been in business since 1886,” O’Connor said. “We have a very tenured workforce of more than 300 people who live and breathe our values of teamwork, quality and creative problem solving. I am extremely confident and optimistic about our future.”

For additional information about the reorganization, please visit: http://pacer.psc.uscourts.gov or https://cases.primeclerk.com/congoleum/Home-Index.

About Congoleum

Since 1886 Congoleum Corporation has been committed to developing innovative flooring products that push the industry forward. Congoleum holds numerous patents for novel creations over the years, and these patents have resulted in products that are like no others in the industry.

Congoleum manufactures residential and commercial resilient products that are engineered with state-of-the-art manufacturing equipment in New Jersey and Pennsylvania and that demonstrate Congoleum’s quality and design leadership. With more than 5,000 retailers selling Congoleum products across North America, Congoleum is proud of its strong and iconic past, energized by the future and as always, unwavering in its commitment to quality, design and innovation.

Share article on social media or email:

ThePersecuted.org Releases Article on Inequality in South Korea and the Coronavirus Response


News Image

The Republic of South Korea has shined internationally in its response to the coronavirus outbreak. They have received ample praise for their aggressive response to the virus; but there have also been accusations of human rights and religious freedom violations.

The first case of coronavirus in the country was discovered on January 20, 2020. This is the same as for the US.

As of this writing, Korea has had 13,417 cases and 289 deaths. In comparison, the United States has had 3.29 million cases with 137,000 deaths. In other words, the US has 474 times the deaths and 245 times the cases as Korea.

The South Korean leadership learned from the past, adjusting laws after the 2015 MERS outbreak. They took the outbreak seriously, and the message was consistent between scientists and politicians. In other words, people followed instructions to wear masks and isolate. They had widespread contact tracing, and they opened dedicated testing and treatment centers.

For these reasons, Korea has served as a sample for the world. However, their response has been questioned by several analysts. Not in regards to technologies used, but with respect to human rights and religious freedom.

The event that put South Korea on the map was an outbreak in the city of Daegu. Though the first case had appeared on January 20th, the government was reluctant to close its borders to China at the time. Korea did eventually take the outbreak seriously, as mentioned above, but not until several weeks later.

As a result, the virus continued to make its way around, infecting a member of the Shincheonji church, where the virus spread in mid-February to over 4,000 other congregants. Immediately, the government aggressively traced and tested over 200,000 members.

Since that time, the group has stopped all gatherings and offered to contribute financially to the efforts to stop the virus. The 4000+ members who recovered from the virus offered to donate plasma to support vaccine and therapeutics research.

With the spirit of the Korean people to work together as we’ve seen these last few months, there is a promising future of reforming and addressing the inequalities to make a more equitable Korea. But that change will require the voices of the people and the action of their government. Read more about solving South Korea’s systemic inequality issue.

#     #     #

ABOUT THE PERSECUTED:

The Persecuted is a news source dedicated to the factual research and analysis of human rights violations. For more information, visit https://thepersecuted.org/.

Share article on social media or email:

Medial EarlySign and Centric Consulting Join Forces to Increase Hospital Adoption of Clinical AI Solutions


“We see tremendous value in EarlySign’s platform which utilizes machine learning technology to facilitate proactive and strategic interventions for patients at high risk of a range of serious medical conditions,” said Centric’s National Healthcare Practice Lead Marcie Stoshak-Chavez, MD.

Medial EarlySign, a leader in AI-based clinical data solutions to aid in the early detection and prevention of high-burden diseases, and Centric Consulting, a business and technology consulting firm, today announced a partnership to enable US-based hospitals and healthcare organizations to utilize existing data in order to identify and prioritize patients for care.

Combining Centric’s management consulting services with EarlySign’s clinically validated AI-powered solutions, the two companies will work together to help healthcare organizations utilize data-backed insights in order to prioritize patient procedures, deliver focused interventions and re-engage populations.

EarlySign’s Infectious Disease bundle will be a primary focus, given the ongoing COVID-19 pandemic and the imminent arrival of flu season.

“Assisting hospitals in navigating clinical, operational and technology adoption challenges and providing outcome-focused care has always been of utmost importance at Centric. We see tremendous value in EarlySign’s platform which utilizes machine learning technology to help our clients facilitate proactive and strategic interventions for patients at high risk of a range of serious medical conditions,” said Marcie Stoshak-Chavez, MD, National Healthcare Practice Lead at Centric. “EarlySign’s validated framework of clinical solutions is perfectly aligned to address our clients’ immediate and long-term artificial intelligence strategies.”

The partnership follows the recent launch of EarlySign’s Back2Care suite of clinical data solutions and will provide hospitals with the tools to identify and prioritize high-risk patients and implement strategies for re-engagement of services.

The suite offers several solutions aimed at high-burden diseases, including the Infectious Disease bundle, Admissions bundle, Diabetes + Complications bundle, and an Early Detection bundle for diseases such as lung and colorectal cancer.

By using routine medical data collected over the course of care and drawing clinical insights into the best course of action for patients, healthcare organizations can optimize resources to provide more personalized and focused care.

“Working collaboratively with Centric to help drive transformational change will allow us to further our goal of advancing proactive healthcare and keeping populations healthy,” said Jeremy Orr MD, CEO of Medial EarlySign. “We are looking forward to further expanding our reach by engaging with Centric’s broad network to support hospitals in improving patient outcomes and navigating the transition back to necessary screening and care.”

ABOUT CENTRIC CONSULTING

Centric Consulting is a management consulting firm that guides you in the search for answers to complex digital, business and technology problems by asking tough questions, leading crucial conversations and blending our experts with yours. As you navigate what’s next, we can help you conquer change, optimize processes, elevate your technology, and compete in a digital world.

Headquartered in Ohio, with locations across the country and India, Centric has earned annual recognition by Forbes as one of America’s Best Management Consulting Firms since 2016. Visit http://www.centricconsulting.com to learn more.

Connect with Centric Consulting: LinkedIn | Twitter | Facebook | Instagram | YouTube

ABOUT MEDIAL EARLYSIGN

Medial EarlySign helps healthcare systems with early detection and prevention of high-burden diseases. Their suite of outcome-focused software solutions (AlgoMarkers™) find subtle, early signs of high-risk patient trajectories in existing lab results and ordinary EHR data already collected in the course of routine care. EarlySign’s AlgoMarkers and AI-based solutions can help clients identify and prioritize patients at high risk for a broad range of conditions. The algorithmic models developed using the company’s machine learning approach are supported by peer-reviewed research published by internationally recognized health organizations and hospitals. Founded in 2013, Medial EarlySign is headquartered in Tel Aviv, Israel with US headquarters in Colorado. For more information, please visit https://earlysign.com/.

Follow Medial EarlySign on LinkedIn: Medial EarlySign and Twitter: @MedialEarlySign

Share article on social media or email:



NeoTract Designates Dr. Joshua Perkel as UroLift® Center of Excellence


News Image

“We are proud to name Dr. Joshua Perkel as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Joshua Perkel, M.D., Urology Specialists of Georgia in Macon, GA has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Perkel has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are proud to name Dr. Joshua Perkel as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “The UroLift System is a safe and effective treatment that allows physicians to treat men in-office under local anesthesia, so they can experience lasting symptom relief within days after receiving treatment.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2. McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Surgio Health Featured in an Article Regarding Centura Health Making Innovative Improvements to the SPD Processes


News Image

This era of surgical downtime is the ideal moment for SPDs to refine their processes and prepare for the reopening of elective cases.

Surgio HealthTM, a surgical logistics and instrument tracking management software company, was featured in an article posted by Elizabeth Hofheinz, M.P.H., M.Ed. at OrthoSpineNews related to the proactive steps Centura Health is taking to stay ahead of the bioburden curve in their 17-facility network serving Colorado and western Kansas.

Daniel Whetten, Supply Chain Manager at Centura Health, states, “This era of surgical downtime is the ideal moment for SPDs to refine their processes and prepare for the reopening of elective cases. Instead of furloughing SPD staff, hospitals can have them engage in thoughtful planning so that they can approach cases in a methodical manner instead of always putting out fires.”

This is a critical topic highlighted by an example of a sterilization technician working at Goshen Health in Indiana that skipped one step in a multi-step cleaning process of surgical equipment resulting in more than 1,000 patients potentially being exposed to HIV or hepatitis.

Chris Stewart, CEO of Surgio Health, states, “Like the rest of us, hospital administrations are feeling significant pressure these days. The immediate impact Surgio provides is a sense of control over SPD processes and vendor interaction with your facility…and that extends to a heightened sense of control over patient safety. Since elective surgeries have slowed or have been canceled due to COVID-19, this is the perfect opportunity for SPDs to address ways to improve on departmental processes, workflows and procedures. Vendors dropping off dirty and incomplete instrument sets, SPD staff rushing through the decontamination, cleaning and sterilization process because the OR calls and needs instrument tray’s ASAP…all of that can become a thing of the past with Surgio’s suite of interdepartmental solutions.”

Surgio Health is aware of the complexities and vulnerabilities present in hospital SPDs and the wider surgical supply chain. The Surgio Platform transforms your SPD from a necessary cost center to an OR optimization tool that positively impacts your healthcare value equation.

Chris Allen: “The Surgio platform is nimble and able to respond to what we need. In developing it with Centura, they did not just do an overlay of a computer program on top of what we were already doing. They forced us to take a step back and think, ‘If we can have the moon what would that look like?’”

About Surgio Health

Sterile Processing Departments (SPD) are the lifeblood of the OR’s they support; constantly in motion and under pressure to respond to OR needs at a moment’s notice. One misstep in workflow could lead to a sentinel event that can be detrimental to a hospital, their system, and worst of all: the patient.

Enter Surgio Health — a managed software solution that applies modern technologies to digitally govern process, track instruments, educate and measure Sterile Processing Departments best practice. Surgio is a management hub unique to the healthcare space that brings every influencer, from manufacturer to the operating room, into alignment under one simple, easy-to-use platform. Raise the standards of protection for your hospital and the patients you serve and transform your SPD from a necessary cost center to a department that positively impacts the healthcare value equation.

Share article on social media or email:

Gables Residential Announces Executive Promotions Across the Company


Gables Residential, a leader in the management and development of multifamily communities, recently announced several key promotions of senior leaders within the organization.

Gables is pleased to announce the promotion of Donna Summers to President of Gables Management Company. Donna will lead the operations of the company, while taking on additional responsibilities to grow the portfolio and drive operational performance.

Donna has over 34 years’ experience in the property management industry, of which 26 years have been with Gables. She has held numerous Property Management and Operations positions overseeing multiple markets throughout the country. In her most recent role as Senior Vice President, Operations, Donna managed day-to-day operations and revenue management for the Gables owned, joint venture and third-party portfolios.

Gables Chief Executive Officer, Sue Ansel, shares “Donna is a smart, hard-working, and thoughtful leader, dedicated to her team’s success and excellence. She started her career as a leasing associate and expanded her roles and responsibilities over the years through diligent effort. During her tenure with Gables, she has continued to expand her duties and influence, driving operations, and leading our associates. In her new role, I am confident that Donna will continue to build and lead a successful team.”

Donna holds her CPM certification and is an active member of the Institute of Real Estate Management. She has been a speaker at numerous industry events, she served on the Board of Directors for the Apartment Association of Greater Dallas and on the Legislative Committee for AAGD.

“I am humbled and grateful for the opportunity to lead a strong team of operations professionals, including a seasoned team of Senior Vice President’s, while having the opportunity to continue to influence and impact our success here at Gables. Our industry continues to grow and innovate, and I look forward to driving both those processes for our company. I am truly #GablesProud and couldn’t be more thrilled about this opportunity,” said Donna Summers, President of Gables Management Company.

Six other Gables leaders were recently promoted to the role of Senior Vice President. Dawn Severt, Chief Financial Officer stated, “We are incredibly proud and eager to see what this leadership group will accomplish moving forward as we have already experienced the benefits of their past accomplishments. This new senior team of leaders will continue to achieve positive results, while influencing and mentoring their respective teams and all associates.”

Rob Presley, a 31-year veteran of Gables, was named Senior Vice President of Facilities Management and Quality Assurance. He has taken on an increased leadership role by adding the Quality Assurance department to his current responsibilities, including Facilities Management and Procurement.

Rob has served as a positive role model for many Gables associates as he has demonstrated that hard work, persistence and commitment generate success as he has worked his way up through the Gables organization, originally starting as a service tech in Memphis in 1988.

Gigi Giannoni, overseeing the marketing and public relations department, has been promoted to Senior Vice President, Customer Experience. Gigi has over 33 years’ experience directing extraordinary brand value, with over 10 years at Gables. Gigi continues to lead the efforts on the digital, marketing, brand and PR front while driving innovation and service. In her new role, she will continue with those responsibilities while leading new projects that will provide greater levels of customer service and enhance the consistency and expectations relevant to the customer experience.

The Gables operations team has also promoted three remarkable leaders that will oversee the success of the Gables operating portfolio:

Greg Gasior has been promoted to Senior Vice President of Operations. Greg has been with Gables for over 25 years and has held many significant roles during his tenure. Greg has been extremely influential throughout his tenure with Gables on many fronts from development and design to operational protocol and strategic alliances. Prior to his promotion, in addition to operations, Greg took on a role facilitating the design efforts on Gables renovations and new lease-ups working nationally with the investment and design teams. In his new role, Greg will be responsible for overseeing the east region including Massachusetts, D.C., Maryland, Virginia, Georgia, and Florida.

Mary Hollands has been promoted to Senior Vice President of Third-Party Operations. Mary started with Gables as a leasing associate and has assumed increased responsibilities over the past 24 years, taking over the leadership of growing Gables third-party business and client services. She has brought structure, passion, and success to the efforts of growing the third-party business model, while developing, enhancing, and maintaining strong client relationships.

Melanie Trapnell has been promoted to Senior Vice President of Operations overseeing the west region including Texas, Colorado, and California. Melanie is a rising leader within the Operations team. Over the last two years, her tenacity and drive have inspired others while she has taken on the responsibilities for many task forces and strategic initiatives.

Melanie’s involvement in these task forces and initiatives has led to the successful implementation of new programs that enhance the day-to-day operations of the company.

Jorgen Punda has been promoted to Senior Vice President of Investments. He has been a leader in the Gables D.C. office since joining the company over 13 years ago. Jorgen has led the development of many successful new projects in the D.C. market and has served as the key driver of Gables’ expansion in the Boston market. Jorgen exhibits cross-functional teamwork at its best working through each new development project in a truly collaborative fashion.

“Jorgen is a key thought leader on the Gables Investments team with a keen eye for creating company value through new real estate developments. Jorgen crafts projects that capture the essence of the local environment while simultaneously enhancing the neighborhood. We look forward to his continued success and leadership,” stated John Akin, Chief Investment Officer.

About Gables Residential

Gables Residential is an award-winning, vertically integrated, real estate company and privately held REIT specializing in the development, construction, ownership, acquisition, financing, and management of multifamily and mixed-use communities. Gables Residential owns, develops, and manages communities in high-growth U.S. markets such as Atlanta, Austin, Boston, Dallas, Denver, Houston, South Florida, Southern California and metropolitan Washington, D.C. Gables also provides third party management services in the New York, Baltimore, Frederick, Tampa, Phoenix, Seattle, Charlotte, Central and North Florida markets.

Gables manages approximately 30,000 apartment homes and approximately 225,000 square feet of retail space and has received national recognition for excellence in development, construction, management, sales, marketing, training, and benefits. These achievements reflect the impact of Gables’ experienced and dedicated team members, its superior knowledge of the markets served, and its expertise in development and management. For additional information about the company and its real estate portfolio and services, visit http://www.gables.com.

Under the Weather® introduces the all-new ShieldPod™ Personal, Portable, Wearable Protective Pod


News Image

With 10-plus years’ experience developing a wide range of portable, pop-up Pods, plus manufacturing capability and in-house product design, UTW is uniquely positioned to develop top-quality products which fit everchanging consumer needs and desires

Under the Weather®(UTW) Chief Executive Officer Rick Pescovitz announced the addition of the all-new ShieldPod™ to the company’s lineup of Pods.

“Our newest COVID-19 product, the ShieldPod™, was designed originally to help protect healthcare workers (MediPod™) from possible COVID-19 exposure but it generated so much buzz and customer requests outside the healthcare industry that we modified the style to accommodate anyone looking for added peace of mind or practicing safe social distancing” adds Pescovitz.

The patent-pending design is a lightweight, protective barrier with a slim profile that pops open and folds flat in seconds. It’s easy to wear, use and store, slips easily over the head with clear panels on three sides for 270° viewing. Padded, adjustable shoulder straps, a waist belt, raised front panel, large armholes on two sides and open bottom offer full range of movement and more options for hand placement whether you’re sitting or walking around. The trim is a neutral dark gray.

“With 10-plus years’ experience developing a wide range of portable, pop-up Pods, plus manufacturing capability and in-house product design, UTW is uniquely positioned to develop top-quality products which fit everchanging consumer needs and desires,” said Kelly Mahan, UTW president. “We also have a legion of loyal brand advocates that helps us by testing our products and providing feedback which ensures the design and quality of our pods is top notch.”

The potential use cases for the ShieldPod are endless, such as: Customer-facing retail employees; teachers; call center employees; taxi and ride-share drivers; church groups; public transportation employees; subway and train commuters; air travelers; workplace huddles; public servants; caregivers; nursing and retirement homes; urban dwellers; and more.

Like all UTW Pods, the ShieldPod uses one-piece wire frame construction, so it’s flexible, pops open and folds down in seconds, with zero assembly required. ShieldPod wearers, and others around them, are protected in an instant.

Thanks to early rave reviews from product testers, including educators, checkout staff and transportation workers, the ShieldPod is in high demand. Affordably priced at $79.99 USD. It is currently being sold as a pre-order exclusively at UTWPods.com. Fulfillment for pre-orders is expected to begin mid-to-late July 2020.

About Under the Weather

The brand of choice for outdoor enthusiasts the world over, Under the Weather has been home to the original pop-up WeatherPod™ since it was established in 2010 in Cincinnati, Ohio. First to market, Under the Weather’s mission is to provide innovative weather-protection solutions for backpackers, campers, sports parents, tailgating fans, music festival buffs and anyone determined to “Be There. Weather, or Not.™”

Under the Weather has been featured on ABC’s “Shark Tank”; NBC’s “Today” show; “The Ellen DeGeneres Show”; the “Rachael Ray Show”; Hallmark Channel’s “Home & Family” and Weather Channel’s “AMHQ: America’s Morning Headquarters.”

Visit UTWPods.com for more information. Stay connected with Under the Weather on Facebook (fb.me/UTWPods), Instagram (@UTWPods) and Twitter (@UTWPods).

Share article on social media or email:



GRIPBELL Receives U.S. Patent for Its New Hybrid Elite Performance Tool Sets; Revolutionary Fitness Product Line to be Released This Fall


GRIPBELL Revolutionary Fitness Product Line

“Everyone said a patent would be nearly impossible to harness, so we’re particularly thrilled to receive one,” said Ronald Obray, CEO of GRIPBELL.

The company also is awaiting approval of several other U.S. and international patents on its technology. It has filed with the Patent Cooperation Treaty (PCT) to protect the weight system in countries governed by the World Trade Organization and has filed a continuation patent application from its issued utility patent.

GRIPBELL’s handheld products are the most versatile, highest-quality fitness products ever built for gym or home use. They offer an all-in-one full-body workout and can replace many other handheld gym products, including dumbbells and kettle bells to simplify or intensify cross-training, physical therapy, weightlifting, yoga or interval training sessions.

GRIPBELL products were developed with every type of fitness level in mind. With its simple transportable design, a variety of weights and the potential to be incorporated into multiple types of training, GRIPBELL can enhance any individual fitness program.

“We believe we have built the most radically innovative fitness tools for all ages and fitness levels,” said Ronald Obray, GRIPBELL’s President and CEO. “Everyone said a patent would be nearly impossible to harness, so we’re particularly thrilled to receive one. The GRIPBELL weights are the ideal product to keep in shape at home — now more than ever.”

GRIPBELL’s fitness set is already proven in the marketplace. The company sold 25,000 units during the beta soft launch phase in 2017. Key features of the product include:


  • All-in-one product, consolidates all other handheld, weighted fitness equipment
  • Beautiful streamlined design
  • Color-coded weights from 3 to 90 pounds
  • Training for any age, fitness level or activity
  • Evenly distributed weight makes them easy to handle
  • Made with hypoallergenic materials
  • Easy to transport and lays flat in luggage for ultimate portability
  • Can be used as an isometric tool to build strength and gain more flexibility
  • Training exercise videos from experienced fitness instructors included

The newly issued utility patent is #10,449,404. It joins GRIPBELL’s three trademark registrations to protect the company’s intellectual property. A China patent for the product is pending with approval expected later this year.

“We will aggressively pursue our international patents over the next two years to find highly qualified distribution partners in the top 20 economic countries around the world,” Obray said.

About GRIPBELL

Based in Reno, Nevada, GRIPBELL develops, sells and distributes the revolutionary GRIPBELL products. In response to the increased demand for innovative, full-body, space-saving fitness equipment for all ages and fitness levels, the patent-pending GRIPBELL is a powerful all-in-one Elite Performance fitness tool that can be used at home, at the office, in commercial gyms, or even while traveling. For more information, go to gripbell.com.

SOCIAL MEDIA

Share article on social media or email:

A Conversation on Race & Food Allergy, featuring a panel of food Industry Experts


“For the Health™ is a webinar series creating a dialogue on racial and economic disparities in food allergy. It is my hope that words will move to action and we will see real lasting change.” Emily Brown, CEO

Food Equality Network (FEI), a nonprofit with the mission to improve health and end hunger in individuals diagnosed with food allergies and celiac disease announced the second of it’s “For the Health” webinar series, A Conversation on Race & Food Allergy.

The webinar will be moderated by Karen Palmer of Karen Palmer Coaching. She is a Certified Professional Coach, school operations consultant, and an advocate for food allergy families.

The expert panelists include industry leaders Susie Hultquist of Spokin Inc., Dan Waters of Enjoy Life Foods, Louis & Joanne Giorgi of Natalie Giorgi Sunshine Foundation & Dr. Ruchi Gupta of Northwestern Medicine Center for Food Allergy & Asthma Research (CFAAR).

This free webinar is FRIDAY, JULY 17, 2020 at 11:00 am EST/10:00am CST. Register to attend at “The For the Health™

The “The For the Health™ webinar series was inspired by this Open Letter to the Food Allergy Community written by Emily Brown, CEO of Food Equality Initative, after the murder of George Floyd that has focused the nation’s attention on the public health crisis of police brutality, which targets black men and women.

Emily Brown says this, “The For the Health™ webinar series is creating a dialogue on racial and economic disparities in food allergy. It is my hope that words will move to action and we will see real lasting change.”

Research shows that Black children are 7% more likely to have food allergies compared to white children, are diagnosed less frequently, receive less medical care, and are more likely to experience anaphylaxis.

This For The Health™ webinar is sponsored by Enjoy Life Foods, Natalie Giorgi Sunshine Foundation, the Northwestern University Center For Allergy and Asthma Research and Spokin.

Share article on social media or email: